C07C211/50

Methods of chemical synthesis of diaminophenothiazinium compounds including methylthioninium chloride (MTC)

Methods of synthesizing and purifying certain 3,7-diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methythioninium Chloride (MTC) (also known as Methylene Blue) are provided. ##STR00001##

Methods of chemical synthesis of diaminophenothiazinium compounds including methylthioninium chloride (MTC)

Methods of synthesizing and purifying certain 3,7-diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methythioninium Chloride (MTC) (also known as Methylene Blue) are provided. ##STR00001##

METHOD FOR REMOVING MONOISOCYANATES FROM ORGANIC SOLUTION

Monoisocyanate impurities are removed from a process stream obtained when solvent is separated from a polyisocyanate product. The monoisocyanates are reacted with amine compounds at specific molar ratios to produce ureas. The ureas can be discarded by burning, landfilling or otherwise. Alternatively the ureas can be recycled back into the polyisocyanate manufacturing process, where they are formed into biuret compounds that can remain with the polyisocyanate product.

METHOD FOR REMOVING MONOISOCYANATES FROM ORGANIC SOLUTION

Monoisocyanate impurities are removed from a process stream obtained when solvent is separated from a polyisocyanate product. The monoisocyanates are reacted with amine compounds at specific molar ratios to produce ureas. The ureas can be discarded by burning, landfilling or otherwise. Alternatively the ureas can be recycled back into the polyisocyanate manufacturing process, where they are formed into biuret compounds that can remain with the polyisocyanate product.

CURABLE RESIN COMPOSITION AND FIBER REINFORCED RESIN MATRIX COMPOSITE MATERIAL
20210403637 · 2021-12-30 ·

A curing agent composition contains at least one multifunctional aromatic amine that forms a crystalline solid at 25° C., and at least one halo-substituted diethyltoluenediamine, in an amount effective to inhibit crystallization of the at least one multifunctional aromatic amine. A curable resin composition contains at least one epoxy compound having at least two epoxide groups per molecule of the epoxy compound and the curing agent composition. Methods for inhibiting phase separation of a curing agent composition or curable resin composition that contains at least one multifunctional aromatic amine that forms a crystalline solid at 25° C. include a step of adding to the respective composition at least one halo-substituted diethyltoluenediamine in an amount effective to inhibit crystallization of the at least one multifunctional aromatic amine. The compositions and methods are useful in making fiber reinforced resin matrix composite articles.

CURABLE RESIN COMPOSITION AND FIBER REINFORCED RESIN MATRIX COMPOSITE MATERIAL
20210403637 · 2021-12-30 ·

A curing agent composition contains at least one multifunctional aromatic amine that forms a crystalline solid at 25° C., and at least one halo-substituted diethyltoluenediamine, in an amount effective to inhibit crystallization of the at least one multifunctional aromatic amine. A curable resin composition contains at least one epoxy compound having at least two epoxide groups per molecule of the epoxy compound and the curing agent composition. Methods for inhibiting phase separation of a curing agent composition or curable resin composition that contains at least one multifunctional aromatic amine that forms a crystalline solid at 25° C. include a step of adding to the respective composition at least one halo-substituted diethyltoluenediamine in an amount effective to inhibit crystallization of the at least one multifunctional aromatic amine. The compositions and methods are useful in making fiber reinforced resin matrix composite articles.

P62-ZZ chemical inhibitor

A method for treating a p62-mediated disease (e.g., multiple myeloma) in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound.

P62-ZZ chemical inhibitor

A method for treating a p62-mediated disease (e.g., multiple myeloma) in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound.